|
1
|
Roder DM: The epidemiology of gastric
cancer. Gastric Cancer. 5(Suppl 1): S5–S11. 2002. View Article : Google Scholar
|
|
2
|
Cervantes A, Roda D, Tarazona N, Roselló S
and Pérez-Fidalgo JA: Current questions for the treatment of
advanced gastric cancer. Cancer Treat Rev. 39:60–67. 2013.
View Article : Google Scholar
|
|
3
|
Mukhtar RA, Nseyo O, Campbell MJ and
Esserman LJ: Tumor-associated macrophages in breast cancer as
potential biomarkers for new treatments and diagnostics. Expert Rev
Mol Diagn. 11:91–100. 2011. View Article : Google Scholar
|
|
4
|
Noy R and Pollard JW: Tumor-associated
macrophages: From mechanisms to therapy. Immunity. 41:49–61. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bingle L, Brown NJ and Lewis CE: The role
of tumour-associated macrophages in tumour progression:
Implications for new anticancer therapies. J Pathol. 196:254–265.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giraudo E, Inoue M and Hanahan D: An
amino-bisphosphonate targets MMP-9-expressing macrophages and
angiogenesis to impair cervical carcinogenesis. J Clin Invest.
114:623–633. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Delgado M and Ganea D: Vasoactive
intestinal peptide: A neuropeptide with pleiotropic immune
functions. Amino Acids. 45:25–39. 2013. View Article : Google Scholar
|
|
9
|
Vacas E, Bajo AM, Schally AV,
Sánchez-Chapado M, Prieto JC and Carmena MJ: Vasoactive intestinal
peptide induces oxidative stress and suppresses metastatic
potential in human clear cell renal cell carcinoma. Mol Cell
Endocrinol. 365:212–222. 2013. View Article : Google Scholar
|
|
10
|
Yang J, Shi QD, Song TB, Feng GF, Zang WJ,
Zong CH and Chang L: Vasoactive intestinal peptide increases VEGF
expression to promote proliferation of brain vascular endothelial
cells via the cAMP/PKA pathway after ischemic insult in vitro.
Peptides. 42:105–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Delgado M and Ganea D: Vasoactive
intestinal peptide prevents activated microglia-induced
neurodegeneration under inflammatory conditions: Potential
therapeutic role in brain trauma. FASEB J. 17:1922–1924.
2003.PubMed/NCBI
|
|
12
|
Delgado M, Robledo G, Rueda B, Varela N,
O'Valle F, Hernandez-Cortes P, Caro M, Orozco G, Gonzalez-Rey E and
Martin J: Genetic association of vasoactive intestinal peptide
receptor with rheumatoid arthritis: Altered expression and signal
in immune cells. Arthritis Rheum. 58:1010–1019. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Delgado M and Ganea D: Cutting edge: Is
vasoactive intestinal peptide a type 2 cytokine? J Immunol.
166:2907–2912. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Delgado M and Ganea D: Inhibition of
endotoxin-induced macrophage chemokine production by VIP and PACAP
in vitro and in vivo. Arch Physiol Biochem. 109:377–382. 2001.
View Article : Google Scholar
|
|
15
|
Gomariz RP, Arranz A, Abad C, Torroba M,
Martinez C, Rosignoli F, Garcia-Gómez M, Leceta J and Juarranz Y:
Time-course expression of Toll-like receptors 2 and 4 in
inflammatory bowel disease and homeostatic effect of VIP. J Leukoc
Biol. 78:491–502. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Arranz A, Juarranz Y, Leceta J, Gomariz RP
and Martínez C: VIP balances innate and adaptive immune responses
induced by specific stimulation of TLR2 and TLR4. Peptides.
29:948–956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laburthe M and Couvineau A: Molecular
pharmacology and structure of VPAC Receptors for VIP and PACAP.
Regul Pept. 108:165–173. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Brenneman DE: Neuroprotection: A
comparative view of vasoactive intestinal peptide and pituitary
adenylate cyclase-activating polypeptide. Peptides. 28:1720–1726.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Voice JK, Dorsam G, Chan RC, Grinninger C,
Kong Y and Goetzl EJ: Immunoeffector and immunoregulatory
activities of vasoactive intestinal peptide. Regul Pept.
109:199–208. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Collado B, Carmena MJ, Clemente C, Prieto
JC and Bajo AM: Vasoactive intestinal peptide enhances growth and
angiogenesis of human experimental prostate cancer in a xenograft
model. Peptides. 28:1896–1901. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Balkwill F: TNF-α in promotion and
progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wong CK, Ho CY, Ko FW, Chan CH, Ho AS, Hui
DS and Lam CW: Proinflammatory cytokines (IL-17, IL-6, IL-18 and
IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients
with allergic asthma. Clin Exp Immunol. 125:177–183. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aktan F: iNOS-mediated nitric oxide
production and its regulation. Life Sci. 75:639–653. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao
YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, et al:
Tumor-associated macrophage-induced invasion and angiogenesis of
human basal cell carcinoma cells by cyclooxygenase-2 induction. J
Invest Dermatol. 129:1016–1025. 2009. View Article : Google Scholar
|
|
25
|
Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng
Q and Wang H, Chen J and Wang H: Tumor-associated macrophages
recruit CCR6+ regulatory T cells and promote the
development of colorectal cancer via enhancing CCL20 production in
mice. PLoS One. 6:e194952011. View Article : Google Scholar
|
|
26
|
Caillou B, Talbot M, Weyemi U,
Pioche-Durieu C, Al Ghuzlan A, Bidart JM, Chouaib S, Schlumberger M
and Dupuy C: Tumor-associated macrophages (TAMs) form an
interconnected cellular supportive network in anaplastic thyroid
carcinoma. PLoS One. 6:e225672011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY,
Shun CT, Tsai MF, Chen CH and Yang PC: Tumor-associated
macrophages: The double-edged sword in cancer progression. J Clin
Oncol. 23:953–964. 2005. View Article : Google Scholar
|
|
28
|
Martinez FO, Sica A, Mantovani A and
Locati M: Macrophage activation and polarization. Front Biosci.
13:453–461. 2008. View
Article : Google Scholar
|
|
29
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pollard JW: Tumour-educated macrophages
promote tumour progression and metastasis. Nat Rev Cancer. 4:71–78.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Khorana AA, Ryan CK, Cox C, Eberly S and
Sahasrabudhe DM: Vascular endothelial growth factor, CD68, and
epidermal growth factor receptor expression and survival in
patients with Stage II and Stage III colon carcinoma: A role for
the host response in prognosis. Cancer. 97:960–968. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Strojnik T, Kavalar R, Zajc I, Diamandis
EP, Oikonomopoulou K and Lah TT: Prognostic impact of CD68 and
kallikrein 6 in human glioma. Anticancer Res. 29:3269–3279.
2009.PubMed/NCBI
|
|
33
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Delgado M, Abad C, Martinez C, Leceta J
and Gomariz RP: Vasoactive intestinal peptide prevents experimental
arthritis by downregulating both autoimmune and inflammatory
components of the disease. Nat Med. 7:563–568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Delgado M and Ganea D: Inhibition of
IFN-γ-induced janus kinase-1-STAT1 activation in macrophages by
vasoactive intestinal peptide and pituitary adenylate
cyclase-activating polypeptide. J Immunol. 165:3051–3057. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ganea D and Delgado M: Vasoactive
intestinal peptide (VIP) and pituitary adenylate cyclase-activating
polypeptide (PACAP) as modulators of both innate and adaptive
immunity. Crit Rev Oral Biol Med. 13:229–237. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
van Horssen R, Ten Hagen TL and Eggermont
AM: TNF-α in cancer treatment: Molecular insights, antitumor
effects, and clinical utility. Oncologist. 11:397–408. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Krejs GJ: VIPoma syndrome. Am J Med.
82B:37–48. 1987. View Article : Google Scholar
|
